gMG Connect
  • Saved

2yr
Eye Segmentation Method for Telehealth: Application to the Myasthenia Gravis Physical Examination

Eye Segmentation Method for Telehealth: Application to the Myasthenia Gravis Physical Examination

Source : https://pubmed.ncbi.nlm.nih.gov/37765800/

Due to the precautions put in place during the COVID-19 pandemic, utilization of telemedicine has increased quickly for patient care and clinical trials. Unfortunately, teleconsultation is closer to a video...

We then use signal processing and filtering to derive robust metrics of ptosis and l ocular misalignment. In our construction, we have prioritized the robustness of the method versus accuracy obtained in controlled conditions in order to provide a method that can operate in standard telehealth conditions. The approach is general and can be...

  • Saved

2yr
Preview of the Immunoglobulin National Society (IgNS) 2023 12th National Conference

The Immunoglobulin National Society (IgNS) will host its 12th national conference at the Sheraton Denver Downtown from Oct. 5 to 8, 2023. This is the premier conference in the immunoglobulin and biologics fields, focusing on education, networking, and advancement.

IgNS conference attendees include clinicians and business leaders in the immunoglobulin and specialty biologics industry. More than 1,200 attendees will have access to over 50 clinical and business sessions throughout the conference. There are several opportunities to obtain Continuing Medical Education credits, as well as hundreds of companies represented in session sponsorships and interactive Expo Hall displays.

We will be covering the conference for you, so check your email for highlights and a wrap-up report. Click above for an exclusive preview of the event.

  • Saved

2yr
Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System - PubMed

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37724594/

ICI may lead to ICIs-associated MG during therapy. Analysis of FAERS data identified signals for AEs of MG with ICI regimens. Practitioners should consider the factors that may increase the...

ICI may lead to ICIs-associated MG during therapy. Analysis of FAERS data identified signals for AEs of MG with ICI regimens. Practitioners should consider the factors that may increase the likelihood of MG. The findings support a continued surveillance and risk factor identification.

  • Saved

2yr
Insights Into the Association Between Myasthenia Gravis and Depression: A Clinical Case Study

Insights Into the Association Between Myasthenia Gravis and Depression: A Clinical Case Study

Source : https://www.cureus.com/articles/175307-insights-into-the-association-between-myasthenia-gravis-and-depression-a-clinical-case-study

Myasthenia gravis (MG) is a serious and debilitating autoimmune disease characterized by muscle weakness, shortness of breath, and issues affecting the eyes, limbs, throat, and speech. Given the intense physical...

The patient has many potential causes of her increased depressive symptoms, including her medications, psychosocial stressors, and her past medical history, in addition to her MG. However, the literature shows higher incidence rates of depression in MG patients compared to both healthy controls and controls with other comparable chronic...

  • Saved

2yr
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome - PubMed

Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37682316/

Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by high titers of antibodies against glutamic acid decarboxylase (GAD) causing impaired GABAergic inhibitory neurotransmission. To date, there is not...

Conclusions/Relevance: Our data suggest that efgartigimod may be considered as a candidate drug for SPS and other autoantibody-mediated neurological disorders.